Core Viewpoint - Shanghai Pharmaceuticals is experiencing a situation of revenue growth without profit increase, prompting a structural optimization strategy [1][8]. Group 1: Company Actions - On February 4, Shanghai Pharmaceuticals announced plans to publicly transfer 30% of its stake in China-America Shanghai Bristol-Myers Squibb Co., with a minimum listing price of 1.023 billion yuan [1][8]. - The company is focusing on innovation, with a new drug pipeline consisting of 56 projects, including 44 innovative drugs [6][14]. Group 2: Shareholder Changes - In October 2025, Shanghai Pharmaceuticals' major shareholder, Shanghai Pharmaceuticals Holding Group, increased its stake from 23.303% to 38.487%, enhancing the stability of the shareholding structure [6][13]. - The second largest shareholder is Yunnan Baiyao, holding 17.95% [6][13]. Group 3: Financial Performance - For the first three quarters of 2025, Shanghai Pharmaceuticals reported revenue of 215.072 billion yuan, a year-on-year increase of 2.60%, while net profit attributable to shareholders was 5.147 billion yuan, up 26.96% [15]. - However, the company's net profit excluding non-recurring items decreased by 26.79%, and operating cash flow fell by 15.56% [15].

Core Viewpoint - Shanghai Pharmaceuticals plans to transfer its 30% stake in the subsidiary China-U.S. Shanghai Bristol-Myers Squibb Pharmaceutical Co., Ltd. through a public listing, with a minimum transfer price of 1.023 billion yuan [1] Group 1: Company Actions - The company will no longer hold any equity in China-U.S. Shanghai Bristol-Myers Squibb after the transaction is completed [1] - The transfer price will be determined based on the results of the public listing, following necessary state-owned asset evaluation procedures [1] Group 2: Financial Impact - The transaction is not expected to have a significant impact on the company's normal operations and financial status [1] - The move is aimed at protecting state-owned asset rights and maximizing asset value, aligning with the interests of the company and all shareholders [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of its Sitagliptin Metformin Extended-Release Tablets, which are intended for adult patients with type 2 diabetes who are undergoing combined treatment with Sitagliptin and Metformin [1] Group 1 - The approved drug is specifically designed for adult patients with type 2 diabetes [1] - The drug was originally developed by Merck Sharp & Dohme and was launched in the United States in 2012 [1]

Group 1 - Shanghai Pharmaceuticals announced that its 28th meeting of the 8th Board of Directors was held on February 4, 2026, via communication [1] - The meeting reviewed the proposal for the public transfer of 30% equity in China-U.S. Shanghai Celgene Pharmaceutical Co., Ltd. [1]

Group 1 - The core viewpoint of the article is that Shanghai Pharmaceuticals plans to optimize its investment structure by publicly transferring its 30% stake in Celgene Corporation through a public listing, with a minimum listing price of approximately RMB 1.023 billion [1] Group 2 - The transfer process will involve a public listing and must complete relevant state-owned asset evaluation management procedures [1] - The final transfer price will be determined based on the results of the public listing [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of its Sitagliptin Metformin Extended-Release Tablets, which is expected to enhance market share and competitiveness in the diabetes treatment sector [1] Group 1: Product Approval - The Sitagliptin Metformin Extended-Release Tablets are intended for adult patients with type 2 diabetes who are currently receiving combined treatment with Sitagliptin and Metformin [1] - The product was originally developed by Merck Sharp & Dohme and was launched in the United States in 2012 [1] - The application for registration was submitted to the National Medical Products Administration in June 2024 and has been accepted [1] Group 2: Financial Investment - The company has invested approximately RMB 8.49 million in research and development for this product [1] Group 3: Market Impact - According to national policies, newly registered generic drugs will receive greater support in areas such as medical insurance payments and procurement by medical institutions [1] - The approval of the Sitagliptin Metformin Extended-Release Tablets is expected to help expand market share and improve competitiveness [1] - The experience gained from this approval will be valuable for the company's future generic drug applications [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Sitagliptin Metformin Extended-Release Tablets, which are intended for adult patients with type 2 diabetes undergoing combined treatment [1] Group 1: Product Approval - The product is approved for production under registration certificate number 2026S00307 [1] - The drug was originally developed by Merck Sharp & Dohme and was launched in the United States in 2012 [1] - The application for registration was submitted to the National Medical Products Administration in June 2024 and was accepted [1] Group 2: Financial Investment - The company has invested approximately RMB 8.49 million in the research and development of this drug [1] Group 3: Market Impact - The approval of this generic drug will receive greater support in areas such as medical insurance payment and procurement by medical institutions, according to national policies [1] - The approval is expected to help expand the market share of the drug and enhance market competitiveness [1] - The experience gained from this approval will be valuable for the company's future generic drug applications [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607) plans to optimize its investment structure and maximize asset value by publicly transferring its 30% stake in Celgene Corporation through a property trading agency, with a minimum listing price of approximately RMB 1.023 billion [1] Group 1 - The company intends to transfer its 30% equity stake in Celgene Corporation [1] - The transfer will be conducted via a public listing process [1] - The minimum listing price is set at approximately RMB 1.023 billion, subject to relevant state evaluation management procedures [1]

格隆汇2月4日丨上海医药(02607.HK)公告，第八届董事会第二十八次会议决议，本次会议审议并通过了 《关于拟公开挂牌转让中美上海施贵宝制药有限公司30%股权的议案》。同意公司通过产权交易所以公 开挂牌方式转让所持标的股权，挂牌转让价格不低于人民币102,319.2万元(需完成相关国有评估管理程 序)，最终转让价格以公开挂牌成交结果为准。 ...

上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司第八屆董事會第二十八次會議決議公告》、《上海醫藥集 團股份有限公司關於擬公開掛牌轉讓中美上海施貴寶製藥有限公司 30%股權的公告》、《上海 醫藥集團股份有限公司關於西格列汀二甲雙胍緩釋片獲得批准生產的公告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2026 年 2 月 5 日 香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠 ...